Effects of dietary zinc supplement during lactation on maternal zinc plasma and milk zinc concentration through 5 months of lactation were examined. One hundred and thirty eight healthy lactating mothers received a weekly 100 mg elemental zinc supplement (ZS, n = 67) or placebo (PG, n = 71) starting one week postpartum in a double blind, randomized design. Milk and plasma zinc concentrations were determined by atomic absorption spectrophotometer. During the course of study, there was not a significantly difference between ZG and PG groups in dietary zinc and energy intake. The mean plasma zinc concentration at 1st week and 5th month were 134 +/- 49.1 and 115.6 +/- 23 microg dL(-1) (PV = 0.005) for PG group, respectively; that of the ZG group these figures were 124.9 +/- 52.8 and 121 +/- 27.1 microg dL(-1) (PV = 0.38), respectively. The mean serum alkaline phosphatase concentration at 1st week and 5th month were 94.8 +/- 37 and 92.6 +/- 29.9 iu L(-1) for PG group, respectively; that of the ZG group these fissures were 90.5 +/- 36 and 90 +/- 29 iu L(-1) (PV = 0.21), respectively. Milk zinc concentration declined significantly over the course of study for two groups, with the sharpest decline occurring during the first 2 months. The mean monthly zinc concentration of ZG group declined from 310 +/- 138 at 1st week to 118 +/- 64 microg dL(-1) at 5th month (declined by 52%). Corresponding means for PG group were 322 +/- 161 and 109 +/- 70 microg dL(-1) (declined by 60%), respectively. Milk zinc concentration significantly different between two groups at 3 and 4 months. A similar study, however, with different zinc dose and administration manner, in zinc marginal deficient lactating mothers is needed to assess the impact of zinc supplementation on milk zinc concentrations.
Some studies suggest that increased homocysteine in blood leads to alterations in coagulation and fibrinolysis; however, the precise mechanism is not clear. The aim of this study was to compare different concentrations of homocysteine and aspirin on fibrinolysis in the plasma of healthy individuals in vitro. Different concentrations of homocysteine (200, 100, and 50 μmol/l) and aspirin (100, 10, and 1 mg/l) were added to the healthy people plasma citrate. They were incubated at 37°C for 24 h. Then, fibrinolysis parameters were analyzed by the turbidimetric procedure at 405 nm. The independent-samples t-test was utilized to compare them (P < 0.05). Findings revealed that homocysteine at 200 μmol/l with aspirin 100 ml/g had significant changes in the lysis maximum velocity (0.150 ± 0.002), half-lysis time (218 ± 5.77), the total lysis time (446 ± 5.77), and lag time in lysis (119 ± 3.60), compared to homocysteine at 200 μmol/l lysis maximum velocity (0.110 ± 0.002), half-lysis time (278 ± 7.63), the total lysis time (515 ± 14.29), and lag time in lysis (176 ± 3.60), respectively (P < 0.05). Homocysteine at 200 μmol/l with aspirin 1 ml/g did not significantly change in either parameter (P > 0.05). Homocysteine at 50 μmol/l with aspirin (100, 10, and 1 mg/l) had significant changes in all fibrinolysis parameters (P < 0.05), compared to homocysteine at 50 μmol/l. The other concentrations were compared in the same way. Aspirin (more than 1 mg/l) had more effect on higher concentrations of homocysteine. Aspirin increased velocity of clot lysis and decreased lysis time of clot in the presence of homocysteine.
Methylglyoxal is a reactive α, β dicarbonyl aldehyde compound that originates from various biochemical pathways. Some studies suggest that increased methylglyoxal in blood leads to changes in fibrinolysis; however, the precise mechanism is not clear. The aim of this study was to compare different concentrations of methylglyoxal and aspirin on fibrinolysis in the plasma of healthy individuals in vitro. Different concentrations of methylglyoxal (5, 50, 100, and 500 μmol/l) and aspirin (1, 10, and 100 mg/l) were added to the plasma citrate. They were incubated at 37°C for 24 h. Then, fibrinolysis parameters were analyzed by the turbidimetric procedure at 405 nm. The Independent Samples t-test was utilized to compare them (P < 0.05). Findings revealed that methylglyoxal at 500 μmol/l with aspirin 100 mg/l had significant changes in the maximum lysis velocity (0.163 ± 0.003), half-time lysis (240 ± 10.00), the total lysis time (485 ± 5.00), lag time in lysis (126 ± 5.77), compared with methylglyoxal at 500 μmol/l (0.104 ± 0.005), (276 ± 5.77), (570 ± 10.00), and (186 ± 5.77), respectively (P < 0.05). Methylglyoxal at 500 μmol/l with aspirin 1 mg/l did not significantly change in either parameter (P > 0.05). Methylglyoxal at 100 μmol/l with aspirin 1 mg/l did not significantly change in either fibrinolysis parameter (P > 0.05), compared with methylglyoxal at 100 μmol/l. Methylglyoxal at 5 μmol/l with aspirin (1, 10, 100 mg/l) changed in all fibrinolysis parameters (P < 0.05), compared with methylglyoxal at 5 μmol/l. The other concentrations were compared in the same way. Aspirin (more than 1 mg/l) had more effect on higher concentrations of methylglyoxal. It increased the velocity of lysis of the clot and shortened clot lysis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.